Results 251 to 260 of about 86,629 (276)

Bortezomib

Reactions Weekly, 2023
openaire   +1 more source

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

Lancet, The, 2020
Sebastian Grosicki, Ivan Spicka, Maria Gavriatopoulou   +2 more
exaly  

Bortezomib

Reactions Weekly, 2015
  +4 more sources

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

Lancet Oncology, The, 2020
Shaji K Kumar, Simon J Harrison, Michele Cavo   +2 more
exaly  

Chemotherapy‐induced peripheral neurotoxicity: A critical analysis

Ca-A Cancer Journal for Clinicians, 2013
Susanna B Park, David Goldstein, Michael L Friedlander   +2 more
exaly  

Bortezomib

Reactions Weekly
  +4 more sources

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Lancet, The, 2019
Phillipe Moreau, Michel M Attal, `Cyrille Hulin   +2 more
exaly  

A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance

Cancer Cell, 2012
Bin Zhou, Mikael Altun, Benedikt M. Kessler   +2 more
exaly  

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

Cancer Cell, 2005
Klaus Podar, Constantine Mitsiades, Hiroshi Yasui   +2 more
exaly  

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

Lancet Oncology, The, 2011
Phillipe Moreau, Sebastian Grosicki, Xavier Leleu   +2 more
exaly